The companies are looking to model gene expression signatures to predict treatments for gastric cancer and improve patient stratification methodologies.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
The new system, called BODE 2, will launch at the end of this year and will replace the existing BODE for the analysis of "big omics" data for research.
Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.
The "augmented intelligence" startup applies machine learning and contextual language processing to make sense of multi-omics datasets and inform drug discovery.
Hatched from the computational genomics lab at Ghent University, BioLizard offers a small but complementary team to tackle AI and molecular pipeline challenges.
The anonymous gift, to be made in annual installments over 10 years, will support interdisciplinary work at the campus's Genomics Institute headquarters.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.
